Omeros (OMER) Net Income towards Common Stockholders (2010 - 2026)
Omeros (OMER) posted Net Income towards Common Stockholders of $4.8 million for Q1 2026, down 26.67% sequentially from $6.6 million in Q4 2025, and up 17.2% YoY from $4.1 million in Q1 2025.
Omeros (OMER) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Omeros has reported Net Income towards Common Stockholders for 17 years, with the latest figure at $4.8 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 17.2% year-over-year to $4.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (down 90.69% YoY) and the FY2025 annual result came in at $1.5 million, down 94.35% from the prior year.
- Net Income towards Common Stockholders declined to $4.8 million in Q1 2026 per OMER's latest filing, from $6.6 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $174.8 million in Q4 2022 and troughed at -$9.7 million in Q3 2025.
- A 5-year average of $18.7 million and a median of $6.6 million in 2025 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2022 and 2025: Net Income towards Common Stockholders surged 73.05% in 2022, then tumbled 298.2% in 2025.
- Over 5 years, Net Income towards Common Stockholders stood at $174.8 million in 2022, then sank by 82.71% to $30.2 million in 2023, then plunged by 82.85% to $5.2 million in 2024, then gained by 26.59% to $6.6 million in 2025, then retreated by 26.67% to $4.8 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered $4.8 million, $6.6 million, and -$9.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Omeros | 1.24 Bn | 1.24 Bn | 27.73 Mn | 6.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.60 Mn |
| Mar 31, 2026 | 4.81 Mn |
| Dec 31, 2025 | 6.56 Mn |
| Sep 30, 2025 | -9.67 Mn |
| Jun 30, 2025 | 466,000.00 |
| Mar 31, 2025 | 4.11 Mn |
| Dec 31, 2024 | 5.18 Mn |
| Sep 30, 2024 | 4.88 Mn |
| Jun 30, 2024 | 9.08 Mn |
| Mar 31, 2024 | 6.67 Mn |
| Dec 31, 2023 | 30.22 Mn |
| Sep 30, 2023 | 13.91 Mn |
| Jun 30, 2023 | 7.00 Mn |
| Mar 31, 2023 | 5.98 Mn |
| Dec 31, 2022 | 174.78 Mn |
| Sep 30, 2022 | 37.34 Mn |
| Jun 30, 2022 | 10.85 Mn |
| Mar 31, 2022 | 6.48 Mn |
| Dec 31, 2021 | 328.94 Mn |
| Sep 30, 2021 | 21.58 Mn |